Spordiff Therapeutics is developing a small molecule to prevent Clostridium difficile (C. diff) antibiotic-associated colitis (AAC), which accounts for 50% of all hospital-acquired infections and results in healthcare costs of around $4 billion annually. The Spordiff approach will prevent onset of AAC by inhibiting germination of C. diff spores, resulting in a new standard of care. Current therapies are used only after illness appears.